Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06669117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 18 to 19 Eligibility criteria expanded, about 77 words · Secondary endpoints revised (11)v7 Show 2 more changesShow less
    • Eligibility criteria expanded, about 77 words
    • Secondary endpoints revised (11)

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 17 to 18 Eligibility criteria revisedv6 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 8 to 17v5
  4. Study sites: 5 to 8v4
  5. Study sites: 2 to 5v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Trial Details
NCT Number NCT06669117
Lead Sponsor Pierre Fabre Medicament
Conditions Solid Tumor, MET Alteration
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov